Another day, another transaction. Is the synthetic biology pioneer better positioned to execute now?
An abstract detailing one of the company's clinical programs was rejected from an important industry meeting.
This Israeli-based pharma company is poised to receive regulatory approval for its first product in the second half of 2019.
The company decided to discontinue an important clinical trial.
The business received a small lifeline from one of its largest shareholders.
Fertilizer companies have largely ignored an approaching wave of digital and biotech competition. Nutrien is taking the risks -- and opportunities -- seriously.
Shares of the synthetic biology pioneer have risen and fallen by double digits many days in recent weeks.
International Paper and WestRock have been humming along, but shares of America's pulp and paper giants are down significantly since the start of 2018.
Many companies will report quarterly earnings later this month and in early May, which makes it a good time for opportunistic investors to be on high alert.
The pharma company announced full-year 2018 operating results.
The pharma company announced full-year 2018 operating results and multiple business updates.
The biopharma announced full-year 2018 operating results.
The biodiesel leader reported full-year 2018 operating results.
The company made two major announcements in the last 24 hours.
An activist investor is attempting to shake up the company.
The fuel cell leader reported full-year 2018 earnings.
The early-stage biotech jumped without any significant news.
The liquid biopsy pioneer has been riding a wave of favorable news lately.
The biosimilar leader announced preliminary sales data for its most important product.
The company announced the pricing of a stock offering. Despite the dilution, it's a well-timed move by management.